摘要
表皮生长因子(EGFR)络氨酸激酶抑制剂(TKIs)改变了对于非小细胞肺癌(NSCLC)的治疗模式。因为表皮生长因子受体激活突变的存在,导致了表皮生长因子受体的分子生物学研究在临床试验中选择病人需要更加准确。尽管如此,一些缺乏EGFR-TKIs响应或者只具有短暂响应的患者也被发现了。这敦促了潜在耐药机制的研究。最重要的是表皮生长因子受体二次突变的存在,例如T790M,或者间叶细胞上皮细胞转变因子(MET)也许可以解释为什么病人最开始对EGFR TKIs响应,而最终却不再响应。已经采取了许多方法,及针对EGFR耐药变异的新药或者MET目前也正在开发。这里我们对表皮生长因子受体生物途径和目前在市场上已经获得批准的EGFR TKIs的临床数据进行了综述和更新。一些正在研究的针对耐药变异或者针对EGFR和其他相关受体的新化合物也进行了综述和讨论。
关键词: 激活突变,表皮生长因子受体,络氨酸激酶抑制剂
Current Drug Targets
Title:Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Volume: 15 Issue: 14
Author(s): Eduardo Castanon, Patricia Martin, Christian Rolfo, Juan P. Fusco, Lucia Ceniceros, Jairo Legaspi, Marta Santisteban and Ignacio Gil-Bazo
Affiliation:
关键词: 激活突变,表皮生长因子受体,络氨酸激酶抑制剂
摘要: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR TKIs. This has urged to study potential resistance mechanisms underneath. The most important ones are the presence of secondary mutations in EGFR, such as T790M, or the overexpression of mesenchymal-epithelial transition factor (MET) that may explain why patients who initially respond to EGFR TKIs, may ultimately become refractory. Several approaches have been taken and new drugs both targeting EGFR resistance-mutation or MET are currently being developed. Here we review and update the EGFR biological pathway as well as the clinical data leading to approval of the EGFR TKIs currently in the market. New compounds under investigation targeting resistance mutations or dually targeting EGFR and other relevant receptors are also reviewed and discussed.
Export Options
About this article
Cite this article as:
Castanon Eduardo, Martin Patricia, Rolfo Christian, P. Fusco Juan, Ceniceros Lucia, Legaspi Jairo, Santisteban Marta and Gil-Bazo Ignacio, Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/138945011514141216092935
DOI https://dx.doi.org/10.2174/138945011514141216092935 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Role of Sequence Variations in <i>AhR</i> Gene Towards Modulating Smoking Induced Lung Cancer Susceptibility in North Indian Population: A Multiple Interaction Analysis
Current Genomics MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Navigational Bronchoscopy in the Evaluation of the Peripheral Pulmonary Nodule.
Current Respiratory Medicine Reviews Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Induction of HT-29 Colon Cancer Cells Apoptosis by Pyrogallol with Growth Inhibiting Efficacy Against Drug-Resistant Helicobacter pylori
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acid Aptamers Based on the G-Quadruplex Structure: Therapeutic and Diagnostic Potential
Current Medicinal Chemistry Editorial [Hot Topic: Target Therapy in Brain Tumours and Metastases (Guest Editors: M. Caraglia and R. Addeo)]
Current Cancer Drug Targets ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Nitroxyl (HNO): A Possible Strategy for Fighting Cancer
Current Topics in Medicinal Chemistry Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Guanine Content of MicroRNAs is Associated with their Tumor- Suppressive and Oncogenic Roles in Lung and Breast Cancers
MicroRNA